In setting hemoglobin A 1c (HbA 1c ) targets, physicians must consider individualized risks and benefits of tight glycemic control (1, 2) by recognizing that the risk-benefit ratio may become unfavorable in certain patients, including the elderly and/or those with multiple comorbidities (3, 4) . Customization of treatment goals based on patient characteristics is poorly understood, partly due to insufficient data on physicians' decisions in setting targets. We used the National Health and Nutrition Examination Survey (NHANES) to analyze patient-reported HbA 1c targets set by physicians and to test whether targets are correlated with patient characteristics.
Data from the NHANES waves 2005-2006, 2007-2008, 2011-2012, and 2013-2014 (the 2009-2010 wave lacked HbA 1c data) comprised 2,641 individuals with self-reported diabetes, of which 1,782 responded to the question, "What does [your doctor] say [your] 'A1C' level should be?" On the basis of the distribution of responses, we analyzed the following targets: ,6%, ,7%, and higher cutoffs (,8%, 9%, and 10%) combined. Using ordered logistic regression, we assessed the influence of age; sex; race; diabetes duration; comorbidities; BMI; variables on physical, mental, and biological health; and health care utilization. We used NHANES sample weights to calculate population rates of target HbA 1c categories across the survey waves. We specified and fit an ordered logistic regression with survey year as a fixed effect to assess whether the covariates influenced target decisions. ANOVA was used to test the differences across the subsamples.
Of 1,782 respondents, 958 (54%) reported a target; others responded that they did not know or that no target was set. Patients in the two unknown target categories were comparable with patients in the known target categories on the majority of variables. Only 4% of our sample reported target HbA 1c .7%. Twenty-six percent of those reporting that a target was not set were over the age 75 years, significantly higher than in other target categories (P , 0.05). Seventy percent of patients who were not aware of their target HbA 1c were nonwhite, which was also significantly higher than in other categories (P , 0.05), except for higher cutoffs. Weighted proportions of response categories show that the proportion responding "do not know" consistently de- . The overall pattern of null effects remained when age and comorbidity were combined. The proportion of target HbA 1c ,7% in young and healthy patients (,45 years old with no comorbidities) was 61% (95% CI 49-71), compared with 62% (95% CI 52-72) in those older than 65 years with at least two comorbidities.
Although self-reported HbA 1c targets (and awareness of targets) have increased over the past decade, the targets remained very low. Additionally, we did not find any evidence that U.S. physicians systematically consider important patient-specific information when selecting the intensity of glycemic control. Rising targets seen during the study period may reflect gradual adoption of the 2010 American Diabetes Association recommendation to encourage more relaxed HbA 1c targets for the elderly (1) and/or changes in quality measures for diabetes control. One parallel explanation is that more contemporary quality metrics permit payers to equally focus on disincentivizing poor HbA 1c control (e.g., HbA 1c .9%), whereas prior metrics were simple binary targets sensitive only to the proportion of patients achieving tight control (HbA 1c ,7%) (5). Such emerging incentive models could have influenced target decisions to shy away from intensive control regardless of the patientlevel characteristics in recent years. Nevertheless, the lack of variation with patient characteristics suggests overreliance on a general approach, without consideration of individual variation in the risks and benefits (or patient preference) of tight control. As "de-adoption" of tight control in diabetes diffuses into practice, it must be targeted to those in whom it is of low value or harmful.
